A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease

作者：Walker Lauren Elizabeth; Griffiths Michael John; McGill Fiona; Lewthwaite Penelope; Sills Graeme John; Jorgensen Andrea^*; Antoine Daniel James; Solomon Tom; Marson Anthony Guy; Pirmohamed Munir^*

来源：Biomarkers, 2017, 22(7): 635-642.

DOI：10.1080/1354750X.2016.1265003

• High-mobility group box 1 (HMGB1)
• biomarker
• cerebrospinal fluid

Aims: To determine whether a correlation exists between paired cerebrospinal fluid (CSF) and serum levels of a novel inflammatory biomarker, high-mobility group box 1 (HMGB1), in different neurological conditions.
Methods: HMGB1 was measured in the serum and CSF of 46 neurological patients (18 idiopathic intracranial hypertension [IIH], 18 neurological infection/inflammation [NII] and 10 Rasmussen's encephalitis [RE]).
Results: Mean serum (+/- SD) HMGB1 levels were 1.43 +/- 0.54, 25.28 +/- 27.9 and 1.89 +/- 1.49 ng/ml for the patients with IIH, NII and RE, respectively. Corresponding mean (+/- SD) CSF levels were 0.35 +/- 0.22, 4.48 +/- 6.56 and 2.24 +/- 2.35 ng/ml. Both CSF and serum HMGB1 was elevated in NII. Elevated CSF HMGB1 was demonstrated in RE. There was no direct correlation between CSF and serum levels of HMGB1.
Conclusion: Serum HMGB1 cannot be used as a surrogate measure for CSF levels. CSF HMGB1 was elevated in NII and RE, its role as a prognostic/stratification biomarker needs further study.

• 出版日期2017